Tolebrutinib

Tolebrutinib

Clinical data
Other names	PRN2246; SAR-442168
Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one
CAS Number	1971920-73-6
PubChem CID	124111565
DrugBank	DB18715
ChemSpider	88298633
UNII	8CZ82ZYY9X
KEGG	D12213
ChEMBL	ChEMBL4650323
Chemical and physical data
Formula	C26H25N5O3
Molar mass	455.518 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
InChI InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1 Key:KOEUOFPEZFUWRF-LJQANCHMSA-N

Tolebrutinib is an investigational new drug that is being evaluated to treat multiple sclerosis.^[1] It is a Bruton's tyrosine kinase (BTK) inhibitor.^[2]

References

1. "Tolebrutinib - Sanofi". AdisInsight. Springer Nature Switzerland AG.
2. Turner TJ, Brun P, Gruber RC, Ofengeim D (June 2024). "Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis". Drugs in R&D. 24 (2): 263–274. doi:10.1007/s40268-024-00468-4. PMC 11315827. PMID 38965189.